Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.
Identifieur interne : 001867 ( PubMed/Checkpoint ); précédent : 001866; suivant : 001868Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.
Auteurs : Melissa M. Coughlin [États-Unis] ; John Babcook ; Bellur S. PrabhakarSource :
- Virology [ 1096-0341 ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (immunologie), Anticorps antiviraux (pharmacologie), Anticorps monoclonaux (immunologie), Anticorps monoclonaux (pharmacologie), Antiviraux (pharmacologie), Attachement viral, Cellules Vero, Concentration inhibitrice 50, Humains, Mutation, Pénétration virale, Tests de neutralisation, Virus du SRAS (immunologie), Virus du SRAS (physiologie).
- MESH :
- immunologie : Anticorps antiviraux, Anticorps monoclonaux, Virus du SRAS.
- pharmacologie : Anticorps antiviraux, Anticorps monoclonaux, Antiviraux.
- physiologie : Virus du SRAS.
- Animaux, Attachement viral, Cellules Vero, Concentration inhibitrice 50, Humains, Mutation, Pénétration virale, Tests de neutralisation.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (pharmacology), Antibodies, Viral (immunology), Antibodies, Viral (pharmacology), Antiviral Agents (pharmacology), Chlorocebus aethiops, Humans, Inhibitory Concentration 50, Mutation, Neutralization Tests, SARS Virus (immunology), SARS Virus (physiology), Vero Cells, Virus Attachment, Virus Internalization.
- MESH :
- chemical , immunology : Antibodies, Monoclonal, Antibodies, Viral.
- chemical , pharmacology : Antibodies, Monoclonal, Antibodies, Viral, Antiviral Agents.
- immunology : SARS Virus.
- physiology : SARS Virus.
- Animals, Chlorocebus aethiops, Humans, Inhibitory Concentration 50, Mutation, Neutralization Tests, Vero Cells, Virus Attachment, Virus Internalization.
Abstract
SARS-CoV causes an acute infection making targeted passive immunotherapy an attractive treatment strategy. We previously generated human mAbs specific to the S1 region of SARS-CoV S protein. These mAbs bind epitopes within the receptor binding domain (RBD) or upstream of the RBD. We show that mAbs recognizing epitopes within the RBD inhibit infection by preventing viral attachment to the cellular receptor. One mAb binds upstream of the RBD and prevents viral entry by inhibiting a post-binding event. Evaluation of several mAbs demonstrated varying ability of the mAbs to select escape mutants when used individually. However, a mixture of antibodies could effectively neutralize a range of mutant viruses. These data strongly suggest that a mixture containing antibodies recognizing distinct regions and targeting more than one step in viral entry is likely to be more effective in neutralizing the virus and suppressing the generation of escape mutants, and thus potentially constitute a highly effective passive immunotherapy.
DOI: 10.1016/j.virol.2009.07.028
PubMed: 19748648
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19748648Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.</title><author><name sortKey="Coughlin, Melissa M" sort="Coughlin, Melissa M" uniqKey="Coughlin M" first="Melissa M" last="Coughlin">Melissa M. Coughlin</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612</wicri:regionArea><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Babcook, John" sort="Babcook, John" uniqKey="Babcook J" first="John" last="Babcook">John Babcook</name></author><author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19748648</idno><idno type="pmid">19748648</idno><idno type="doi">10.1016/j.virol.2009.07.028</idno><idno type="wicri:Area/PubMed/Corpus">001832</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001832</idno><idno type="wicri:Area/PubMed/Curation">001832</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001832</idno><idno type="wicri:Area/PubMed/Checkpoint">001867</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001867</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.</title><author><name sortKey="Coughlin, Melissa M" sort="Coughlin, Melissa M" uniqKey="Coughlin M" first="Melissa M" last="Coughlin">Melissa M. Coughlin</name><affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Microbiology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612</wicri:regionArea><placeName><region type="state">Illinois</region><settlement type="city">Chicago</settlement></placeName><orgName type="university">Université de l'Illinois à Chicago</orgName></affiliation></author><author><name sortKey="Babcook, John" sort="Babcook, John" uniqKey="Babcook J" first="John" last="Babcook">John Babcook</name></author><author><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name></author></analytic><series><title level="j">Virology</title><idno type="eISSN">1096-0341</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (pharmacology)</term><term>Antibodies, Viral (immunology)</term><term>Antibodies, Viral (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>Chlorocebus aethiops</term><term>Humans</term><term>Inhibitory Concentration 50</term><term>Mutation</term><term>Neutralization Tests</term><term>SARS Virus (immunology)</term><term>SARS Virus (physiology)</term><term>Vero Cells</term><term>Virus Attachment</term><term>Virus Internalization</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (pharmacologie)</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Attachement viral</term><term>Cellules Vero</term><term>Concentration inhibitrice 50</term><term>Humains</term><term>Mutation</term><term>Pénétration virale</term><term>Tests de neutralisation</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Viral</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Humans</term><term>Inhibitory Concentration 50</term><term>Mutation</term><term>Neutralization Tests</term><term>Vero Cells</term><term>Virus Attachment</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Attachement viral</term><term>Cellules Vero</term><term>Concentration inhibitrice 50</term><term>Humains</term><term>Mutation</term><term>Pénétration virale</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS-CoV causes an acute infection making targeted passive immunotherapy an attractive treatment strategy. We previously generated human mAbs specific to the S1 region of SARS-CoV S protein. These mAbs bind epitopes within the receptor binding domain (RBD) or upstream of the RBD. We show that mAbs recognizing epitopes within the RBD inhibit infection by preventing viral attachment to the cellular receptor. One mAb binds upstream of the RBD and prevents viral entry by inhibiting a post-binding event. Evaluation of several mAbs demonstrated varying ability of the mAbs to select escape mutants when used individually. However, a mixture of antibodies could effectively neutralize a range of mutant viruses. These data strongly suggest that a mixture containing antibodies recognizing distinct regions and targeting more than one step in viral entry is likely to be more effective in neutralizing the virus and suppressing the generation of escape mutants, and thus potentially constitute a highly effective passive immunotherapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19748648</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0341</ISSN><JournalIssue CitedMedium="Internet"><Volume>394</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Nov</Month><Day>10</Day></PubDate></JournalIssue><Title>Virology</Title><ISOAbbreviation>Virology</ISOAbbreviation></Journal><ArticleTitle>Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.</ArticleTitle><Pagination><MedlinePgn>39-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2009.07.028</ELocationID><Abstract><AbstractText>SARS-CoV causes an acute infection making targeted passive immunotherapy an attractive treatment strategy. We previously generated human mAbs specific to the S1 region of SARS-CoV S protein. These mAbs bind epitopes within the receptor binding domain (RBD) or upstream of the RBD. We show that mAbs recognizing epitopes within the RBD inhibit infection by preventing viral attachment to the cellular receptor. One mAb binds upstream of the RBD and prevents viral entry by inhibiting a post-binding event. Evaluation of several mAbs demonstrated varying ability of the mAbs to select escape mutants when used individually. However, a mixture of antibodies could effectively neutralize a range of mutant viruses. These data strongly suggest that a mixture containing antibodies recognizing distinct regions and targeting more than one step in viral entry is likely to be more effective in neutralizing the virus and suppressing the generation of escape mutants, and thus potentially constitute a highly effective passive immunotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coughlin</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Microbiology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babcook</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Prabhakar</LastName><ForeName>Bellur S</ForeName><Initials>BS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Virology</MedlineTA><NlmUniqueID>0110674</NlmUniqueID><ISSNLinking>0042-6822</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="Y">Virus Attachment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="Y">Virus Internalization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748648</ArticleId><ArticleId IdType="pii">S0042-6822(09)00446-2</ArticleId><ArticleId IdType="doi">10.1016/j.virol.2009.07.028</ArticleId><ArticleId IdType="pmc">PMC7111986</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2009 May;5(5):e1000453</Citation><ArticleIdList><ArticleId IdType="pubmed">19478866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pediatr Infect Dis J. 2004 Nov;23(11):1049-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15545861</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Sep 10;322(1):93-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15313178</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S71-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18820582</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Genet. 2008 Apr;9(4):267-76</Citation><ArticleIdList><ArticleId IdType="pubmed">18319742</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhonghua Yi Xue Za Zhi. 2004 Apr 17;84(8):642-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15130303</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2006 Feb 10;281(6):3198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">16339146</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Apr;82(7):3220-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18199635</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 1998 Feb;53(2):129-39</Citation><ArticleIdList><ArticleId IdType="pubmed">9620205</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2007 Jul;81(14):7410-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17507479</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Pulm Med. 2008 May;14(3):248-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18427249</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2005 Jul 22;333(1):186-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15939399</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biomed Sci. 2003 Nov-Dec;10(6 Pt 2):664-75</Citation><ArticleIdList><ArticleId IdType="pubmed">14631105</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Biotechnol. 2007 Dec;25(12):1421-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18066039</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Sep 30;309(5744):2154-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16195440</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 May 14;279(20):20836-49</Citation><ArticleIdList><ArticleId IdType="pubmed">14996844</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Sep;79(18):11638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">16140741</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8709-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15161975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jan 30;279(5):3197-201</Citation><ArticleIdList><ArticleId IdType="pubmed">14670965</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Microbes Infect. 2008 Jul;10(8):908-15</Citation><ArticleIdList><ArticleId IdType="pubmed">18606245</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Scand J Immunol. 2003 Sep;58(3):277-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12950672</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2003 Dec 26;312(4):1159-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14651994</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation><ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Jul;3(7):e237</Citation><ArticleIdList><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):797-801</Citation><ArticleIdList><ArticleId IdType="pubmed">15642942</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1059-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15306390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2008 Nov;4(11):e1000197</Citation><ArticleIdList><ArticleId IdType="pubmed">18989460</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2005 Sep;77(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16032747</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4240-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15010527</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(6):3289-96</Citation><ArticleIdList><ArticleId IdType="pubmed">15731223</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(10):5900-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15857975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2007 Apr 25;361(1):93-102</Citation><ArticleIdList><ArticleId IdType="pubmed">17161858</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 Sep;82(17):8887-90</Citation><ArticleIdList><ArticleId IdType="pubmed">18562523</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Oct 28;310(5748):676-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region><settlement><li>Chicago</li></settlement><orgName><li>Université de l'Illinois à Chicago</li></orgName></list><tree><noCountry><name sortKey="Babcook, John" sort="Babcook, John" uniqKey="Babcook J" first="John" last="Babcook">John Babcook</name><name sortKey="Prabhakar, Bellur S" sort="Prabhakar, Bellur S" uniqKey="Prabhakar B" first="Bellur S" last="Prabhakar">Bellur S. Prabhakar</name></noCountry><country name="États-Unis"><region name="Illinois"><name sortKey="Coughlin, Melissa M" sort="Coughlin, Melissa M" uniqKey="Coughlin M" first="Melissa M" last="Coughlin">Melissa M. Coughlin</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001867 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001867 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19748648
|texte= Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19748648" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |